

## Tailoring to Individual Target Hb Is the Ultimate Solution!



Erythropoiesis-stimulating agent should be considered in below set of patients:1

In dialysis patients with Hb levels between 9.0 and 10.0 q/dL<sup>1</sup>

In pre-dialysis patients with Hb levels <10 g/dL<sup>1</sup>



0-



**85%** of patients treated with darbepoetin maintained Hb level in the target range.<sup>2</sup>

 $0^{\prime}$ 

## Change for Better...Change to



## **Abbreviations**

CKD: Chronic kidney disease; CVD: Cardiovascular disease; Hb: Hemoglobin; HRQoL: Health-related quality of life; KDIGO: Kidney Disease Improving Global Outcomes.

## References

1. KDIGO clinical practice guideline for Anemia in chronic kidney disease. *Kidney Int Suppl.* 2012;2(4):279–335. **2.** Mann J, Kessler M, Villa G, *et al.* Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. *Clin Nephrol.* 2007;67:140–148.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy's Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy's.